Dystonia

1. Topic Overview (Clinical Overview)

Summary

Dystonia is a hyperkinetic movement disorder characterised by sustained or intermittent muscle contractions causing abnormal, often repetitive movements, postures, or both. [1] The involuntary muscle contractions result in twisting, repetitive movements and/or abnormal postures that are frequently painful and can be task-specific or action-induced. [2]

Dystonia affects approximately 16-30 per 100,000 individuals globally, making it the third most common movement disorder after essential tremor and Parkinson's disease. [3] The condition can be classified by:

• Distribution (Focal, Segmental, Multifocal, Hemidystonia, Generalised)
• Age of Onset (Early-onset less than 26 years, Late-onset > 26 years)
• Aetiology (Primary/Idiopathic, Secondary/Acquired, Heredodegenerative)

The most common form in adults is Cervical Dystonia (Spasmodic Torticollis), affecting 5-10 per 100,000 individuals, with a female predominance (2:1). [4] A pathognomonic clinical feature is the "Sensory Trick" (Geste Antagoniste) – a voluntary manoeuvre (e.g., touching the chin or face) that temporarily alleviates the abnormal posture through sensory feedback modulation. [5]

First-line treatment for focal dystonia is intramuscular Botulinum Toxin (BoNT) injections, which provide significant symptom relief in 70-90% of patients for approximately 3 months. [6] Acute Dystonic Reactions (drug-induced, commonly from dopamine receptor antagonists like Metoclopramide or Haloperidol) constitute a medical emergency requiring immediate treatment with anticholinergics (Procyclidine 5-10mg IV/IM or Benztropine 1-2mg IV/IM). [7]

All young-onset dystonia (less than 26 years) requires investigation to exclude secondary causes, particularly Wilson's Disease (hepatolenticular degeneration), which is potentially reversible with copper chelation therapy. [8]

Key Facts

• Definition: Sustained or intermittent muscle contractions → Abnormal movements, postures, or both. [1]
• Prevalence: 16-30 per 100,000 (all dystonias); 5-10 per 100,000 (cervical dystonia). [3,4]
• Classification by Distribution: Focal (one region), Segmental (≥2 adjacent), Multifocal (≥2 non-adjacent), Hemidystonia (unilateral), Generalised (trunk + ≥2 regions). [1]
• Most Common Adult Dystonia: Cervical Dystonia (Spasmodic Torticollis). [4]
• Pathognomonic Sign: Sensory Trick (Geste Antagoniste) – tactile manoeuvre temporarily reduces dystonic posture. [5]
• First-Line Treatment (Focal): Botulinum Toxin Type A injections (BoNT-A). [6]
• Acute Dystonic Reaction: Drug-induced emergency. Treat with IV/IM anticholinergics (Procyclidine 5-10mg). [7]
• Exclude in Young Onset: Wilson's Disease (serum caeruloplasmin, 24-hour urinary copper, slit-lamp for Kayser-Fleischer rings). [8]

Clinical Pearls

"The Geste Antagoniste": A patient who touches their chin, cheek, or occiput to relieve involuntary head turning has Cervical Dystonia. This sensory trick is highly specific and helps differentiate dystonia from other movement disorders.

"Oculogyric Crisis = Procyclidine Stat": Forced, sustained upward eye deviation following dopamine antagonist exposure (Metoclopramide, Haloperidol) is an Acute Dystonic Reaction. Give Procyclidine 5-10mg IV immediately.

"Wilson's in Young Dystonia": Always check serum caeruloplasmin and 24-hour urinary copper in dystonia presenting less than 26 years. Wilson's Disease is treatable and potentially reversible.

"Botox Every 12 Weeks": Focal dystonia responds excellently to Botulinum Toxin injections repeated every 3 months. Patients should be counselled that this is a chronic, ongoing treatment.

"Overflow and Mirror Movements": Dystonia often shows overflow (spread to adjacent muscles) and mirror dystonia (contralateral limb involvement during unilateral task), distinguishing it from weakness.

"Task-Specific = Writer's Cramp": Dystonia occurring only during a specific task (e.g., writing, playing an instrument) suggests a task-specific focal dystonia common in occupational settings.

Why This Matters Clinically

Dystonia causes significant physical disability, pain, functional impairment, and psychosocial distress. [9] Early recognition and appropriate treatment can dramatically improve quality of life:

1. Focal Dystonia: Highly treatable with Botulinum Toxin (70-90% response rate). [6]
2. Acute Drug-Induced Dystonia: Immediate recognition and treatment prevents severe distress, aspiration risk (if laryngeal), and respiratory compromise.
3. Wilson's Disease: Failure to investigate young-onset dystonia can miss a life-threatening but treatable condition.
4. Deep Brain Stimulation (DBS): Offers substantial benefit for medically refractory cases, particularly in primary generalised dystonia (DYT1). [10]

---

2. Epidemiology

Prevalence and Incidence

Age Distribution

Sex Distribution

Geographic and Ethnic Variation

• DYT1 (TOR1A mutation): Particularly prevalent in Ashkenazi Jewish population (1 in 2,000 to 1 in 6,000 carrier frequency). [11]
• Dopa-Responsive Dystonia (DYT5): More common in individuals of European and Japanese ancestry.
• X-linked Dystonia-Parkinsonism (Lubag, DYT3): Almost exclusively affects males of Filipino (Panay Island) descent.

---

3. Pathophysiology

Neuroanatomical Substrate

Dystonia results from dysfunction of the basal ganglia-thalamocortical motor circuits, particularly involving:

1. Basal Ganglia: Striatum (caudate, putamen), Globus Pallidus (GPe, GPi), Subthalamic Nucleus (STN), Substantia Nigra.
2. Thalamus: Ventral lateral (VL) and Ventral anterior (VA) nuclei.
3. Motor Cortex: Primary motor cortex (M1), Supplementary motor area (SMA), Premotor cortex.
4. Cerebellum: Emerging evidence suggests cerebellar dysfunction in dystonia pathophysiology. [12]

Pathophysiological Mechanisms

1. Loss of Inhibition

• Reduced surround inhibition in the motor cortex allows unwanted muscle activation. [13]
• Decreased reciprocal inhibition between agonist-antagonist muscle pairs → Co-contraction and abnormal postures.
• Deficient lateral inhibition in the basal ganglia → Overflow movements.

2. Abnormal Plasticity

• Maladaptive neuroplasticity in the sensorimotor cortex, particularly in task-specific dystonias (writer's cramp, musician's dystonia). [14]
• Reorganisation of cortical motor maps with blurred somatotopic representation.
• Enhanced long-term potentiation (LTP) without adequate long-term depression (LTD).

3. Sensory Processing Deficits

• Impaired sensory discrimination (tactile, proprioceptive, visual).
• Abnormal temporal discrimination threshold – difficulty distinguishing closely spaced sensory stimuli.
• Geste antagoniste (sensory trick) operates through normalising sensory feedback to motor circuits. [5]

4. Dopaminergic Dysfunction

• In dopa-responsive dystonia (DYT5/GCH1 deficiency): Impaired dopamine synthesis due to GTP cyclohydrolase I deficiency → Low striatal dopamine.
• Dramatic response to levodopa (often less than 100mg/day) is diagnostic.

5. GABAergic Dysfunction

• Reduced GABA-mediated inhibition in cortical and subcortical circuits.
• Some dystonia responds to GABAergic drugs (benzodiazepines, baclofen).

Molecular Genetics (Selected Primary Dystonias)

Secondary Dystonia Mechanisms

---

4. Classification

By Distribution (Anatomical)

The 2013 Consensus Classification organises dystonia by body region affected: [1]

By Age of Onset

Clinical Rule: Age of onset less than 26 years → Higher likelihood of:

• Genetic cause (DYT1, DYT5, DYT6)
• Progression to generalised dystonia
• Requires investigation for secondary causes (especially Wilson's disease)

By Aetiology

---

5. Clinical Presentation: Common Focal Dystonias

Cervical Dystonia (Spasmodic Torticollis)

Most common focal dystonia in adults. [4]

Blepharospasm

Involuntary, bilateral eyelid closure. Second most common focal dystonia.

Oromandibular Dystonia

Dystonia of the jaw, tongue, and lower face.

Laryngeal Dystonia (Spasmodic Dysphonia)

Dystonia of the vocal cords.

Writer's Cramp (Focal Hand Dystonia)

Task-specific dystonia of the hand/forearm during writing.

---

6. Acute Dystonic Reaction (Drug-Induced Dystonia)

Epidemiology and Risk Factors

Acute Dystonic Reactions (ADR) occur in 2-10% of patients receiving dopamine receptor antagonists. [7]

Causative Drugs

Clinical Features

Onset: Usually within hours to days of drug initiation or dose increase (peak incidence 24-72 hours). Can occur after first dose.

Differential Diagnosis: Exclude seizure, tetanus, encephalitis, hypocalcaemia (tetany), functional/psychogenic.

Emergency Management

Post-Emergency Management:

1. Stop the offending drug (or reduce dose).
2. Oral anticholinergic continuation for 24-48 hours to prevent recurrence (e.g., Procyclidine 5mg PO TDS or Orphenadrine 50mg PO TDS).
3. If antipsychotic required: Switch to lower-risk agent (quetiapine, clozapine) or use prophylactic anticholinergic.

Response: Symptoms typically resolve within 5-30 minutes of IV anticholinergic administration. [7]

---

7. Investigations

When to Investigate

All young-onset dystonia (less than 26 years) requires investigation. [8]

Investigate older-onset dystonia if:

• Hemidystonia (suggests structural lesion)
• Rapid progression
• Atypical features: Cognitive decline, pyramidal signs, cerebellar signs, peripheral neuropathy
• Family history of dystonia or neurological disease
• Lack of response to Botulinum Toxin

Baseline Investigations (Young-Onset less than 26 years)

Additional Investigations (If Indicated)

Neuroimaging (MRI Brain)

---

8. Management

General Principles

1. Identify and Treat Secondary Causes: Wilson's disease (copper chelation), drug-induced (stop drug), dopa-responsive dystonia (levodopa).
2. Botulinum Toxin for Focal/Segmental Dystonia: First-line therapy. [6]
3. Oral Medications for Generalised/Multifocal Dystonia or BoNT Non-responders.
4. Deep Brain Stimulation (DBS) for Severe, Medically Refractory Dystonia. [10]
5. Multidisciplinary Support: Physiotherapy, occupational therapy, speech therapy, psychology/psychiatry (depression, anxiety common).

Botulinum Toxin (BoNT)

Mechanism: BoNT is a neurotoxin produced by Clostridium botulinum that irreversibly blocks acetylcholine release at the presynaptic neuromuscular junction by cleaving SNARE proteins (SNAP-25, syntaxin, synaptobrevin), causing chemical denervation and muscle weakness. [6]

Evidence: Multiple high-quality RCTs confirm BoNT efficacy in focal dystonia. [6]

Oral Medications

Used for generalised dystonia, multifocal dystonia, or BoNT non-responders/contraindications.

Clinical Approach:

• Start with one agent, low dose, titrate slowly.
• Combine drugs if monotherapy insufficient (e.g., Trihexyphenidyl + Baclofen).
• Children/young adults tolerate anticholinergics better than elderly.
• Always trial levodopa in young-onset dystonia to exclude dopa-responsive dystonia (even if Wilson's negative).

Deep Brain Stimulation (DBS)

Surgical neuromodulation for severe, medically refractory dystonia.

Patient Selection: Young, primary generalised (especially DYT1), no fixed contractures, psychologically stable.

Supportive and Allied Therapies

---

9. Specific Dystonia Syndromes

Dopa-Responsive Dystonia (Segawa's Syndrome, DYT5)

Myoclonus-Dystonia Syndrome (DYT11)

X-Linked Dystonia-Parkinsonism (Lubag, DYT3)

---

10. Complications and Prognosis

Complications

Prognosis

---

11. Special Populations

Paediatric Dystonia

Approach to Child with Dystonia:

1. Detailed History: Birth history (hypoxia, prematurity), developmental milestones, drug exposure, family history.
2. Exclude Secondary Causes: Wilson's Disease (> 3 years age), Cerebral Palsy, metabolic (glutaric aciduria), neurodegeneration (NBIA).
3. Trial of Levodopa: Always trial in young-onset dystonia (exclude dopa-responsive dystonia).
4. Genetic Testing: Consider DYT1 (especially if Ashkenazi Jewish, generalised, less than 26 years).
5. Multidisciplinary: Paediatric neurology, genetics, physiotherapy, occupational therapy.

Pregnancy and Dystonia

---

12. Guidelines and Evidence

Key Guidelines

Landmark Studies

---

13. Differential Diagnosis

Distinguish Dystonia from Other Movement Disorders

Conditions Mimicking Dystonia

---

14. Exam Scenarios and Vivas

Scenario 1: Cervical Dystonia Recognition

Stem: A 48-year-old woman presents with 6 months of progressive involuntary turning of her head to the right. She finds that touching her chin temporarily relieves the abnormal posture. Examination reveals torticollis with palpable sternocleidomastoid contraction. What is the diagnosis, pathognomonic sign, and first-line treatment?

Model Answer:

• Diagnosis: Cervical Dystonia (Spasmodic Torticollis) – the most common focal dystonia in adults.
• Pathognomonic Sign: Geste Antagoniste (Sensory Trick) – voluntary tactile manoeuvre (touching chin) that transiently alleviates the dystonic posture. Highly specific for dystonia.
• First-Line Treatment: Botulinum Toxin Type A (BoNT-A) intramuscular injections into overactive neck muscles (e.g., sternocleidomastoid, splenius capitis) guided by clinical examination ± EMG. Repeated every 3 months. Evidence Level A efficacy. [6]

---

Scenario 2: Acute Dystonic Reaction

Stem: A 22-year-old man attends A&E 6 hours after receiving intramuscular metoclopramide for vomiting. He has sustained upward deviation of both eyes, neck twisting, and jaw clenching. He is distressed but fully conscious. What is the diagnosis and immediate management?

Model Answer:

• Diagnosis: Acute Dystonic Reaction (drug-induced dystonia secondary to dopamine D2 receptor blockade by metoclopramide). Specific manifestation: Oculogyric Crisis (forced upward eye deviation).
• Immediate Management:
  1. Procyclidine 5-10mg IV/IM (or Benztropine 1-2mg IV/IM) – anticholinergic. Expect symptom resolution within 5-15 minutes.
  2. Stop the offending drug (metoclopramide).
  3. Observe for symptom resolution.
  4. Discharge with oral anticholinergic for 24-48 hours (e.g., Procyclidine 5mg PO TDS) to prevent recurrence.
  5. Document drug allergy/reaction in patient notes. Avoid dopamine antagonists in future or use prophylactic anticholinergic if essential.

---

Scenario 3: Young-Onset Dystonia Investigation

Stem: A 16-year-old girl presents with 1 year of progressive dystonia affecting her left leg, now spreading to her left arm. MRI brain shows bilateral T2 hyperintensity in the putamen and caudate. What is the most important treatable diagnosis to exclude, and which investigations are required?

Model Answer:

• Diagnosis to Exclude: Wilson's Disease (Hepatolenticular Degeneration) – autosomal recessive disorder of copper metabolism (ATP7B mutation) causing copper accumulation in liver and basal ganglia. Potentially reversible with copper chelation if treated early. [8]
• Investigations:
  1. Serum Caeruloplasmin – Low (less than 20 mg/dL or 0.2 g/L) in 85-95% of Wilson's.
  2. 24-Hour Urinary Copper – Elevated (> 100 μg/24hr or 1.6 μmol/24hr).
  3. Slit-Lamp Examination – Kayser-Fleischer rings (corneal copper deposition) present in ~95% of neurological Wilson's.
  4. Liver Function Tests – Transaminitis, reduced albumin, coagulopathy.
  5. Genetic Testing – ATP7B sequencing (confirmatory).
  6. MRI Brain – T2 hyperintensity in putamen, caudate, thalamus, brainstem ("face of the giant panda" in midbrain).
• Treatment (if confirmed): Copper chelation – D-penicillamine (first-line, 1-2g/day) or Trientine (if penicillamine-intolerant). Zinc acetate (maintenance). Neurological improvement may take 6-24 months. Liver transplant if fulminant hepatic failure.

---

Scenario 4: Dopa-Responsive Dystonia

Stem: A 7-year-old boy presents with progressive difficulty walking over 2 years. His foot turns inward when walking. His mother notes symptoms are worse in the evening and improve after sleep. Examination shows dystonic posturing of the right foot with gait difficulty. What diagnosis should be considered, and how is it confirmed?

Model Answer:

• Diagnosis: Dopa-Responsive Dystonia (Segawa's Syndrome, DYT5) – GTP cyclohydrolase I (GCH1) deficiency causing impaired dopamine synthesis. [15]
• Key Features:
  • Childhood-onset (typically 4-8 years).
  • Lower limb dystonia (gait disorder, foot inversion).
  • Diurnal fluctuation – worse in evening, improves with sleep (pathognomonic).
  • May have brisk reflexes, mild parkinsonism.
• Diagnostic Confirmation:
  1. Therapeutic trial of levodopa (50-100mg/day + carbidopa) → Dramatic, sustained improvement within days (diagnostic). This is both diagnostic and therapeutic.
  2. CSF neurotransmitter metabolites (if available) – Low homovanillic acid (HVA), low neopterin, normal 5-HIAA.
  3. Genetic testing – GCH1 sequencing (confirmatory).
• Treatment: Low-dose levodopa (50-300mg/day). Sustained response without dyskinesia or motor fluctuations (unlike Parkinson's disease). Lifelong treatment. Excellent prognosis.

---

Scenario 5: Deep Brain Stimulation Candidacy

Stem: A 19-year-old woman with genetically confirmed DYT1 dystonia has severe, disabling generalised dystonia despite maximal oral medication (trihexyphenidyl 40mg/day, baclofen 80mg/day). She is wheelchair-bound and requires assistance with ADLs. What surgical option should be considered, what is the target, and what is the expected outcome?

Model Answer:

• Surgical Option: Deep Brain Stimulation (DBS).
• Target: Bilateral Globus Pallidus Internus (GPi) – most effective target for dystonia.
• Indications Met:
  • Severe, medically refractory dystonia.
  • Primary generalised dystonia (DYT1) – best DBS response.
  • Young, no fixed contractures (better prognosis).
• Expected Outcome:
  • 60-90% improvement in Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) in DYT1 patients. [10]
  • Response may be delayed (weeks to months) – requires patience and careful programming.
  • Earlier intervention is better (before fixed skeletal deformities).
• Risks: Intracranial haemorrhage (1-3%), infection (3-5%), lead malposition, stimulation-related side effects (dysarthria, dysphagia, bradykinesia).

---

15. Triage and Referral Pathways

---

16. Patient and Layperson Explanation

What is Dystonia?

Dystonia is a movement disorder where your muscles contract (tighten) involuntarily, causing twisting movements or abnormal postures that you cannot control. It can affect one part of your body (e.g., your neck, eyelids, or hand) or multiple parts.

What Causes It?

The exact cause is often unknown. Dystonia occurs because of abnormal signals from the brain (specifically an area called the basal ganglia) that control muscle movement. Some types are:

• Genetic (inherited from parents).
• Secondary to other conditions (e.g., stroke, certain medications, or a rare condition called Wilson's Disease).
• Idiopathic (no identifiable cause – most common in adults).

What Are the Symptoms?

• Neck turning or tilting (Cervical Dystonia/Torticollis) – most common in adults.
• Involuntary eyelid closure (Blepharospasm) – difficulty keeping eyes open.
• Difficulty writing (Writer's Cramp) – hand cramps or abnormal posture when writing.
• Voice changes (Spasmodic Dysphonia) – strained or breathy voice.
• Jaw, tongue, or mouth movements (Oromandibular Dystonia) – difficulty eating or speaking.

Symptoms often improve with a "sensory trick" – for example, touching your chin may temporarily relieve neck dystonia.

How is it Treated?

1. Botulinum Toxin (Botox) Injections – First-line treatment for focal dystonia (e.g., neck, eyelids). Injections are given into the affected muscles every 3 months. This is very effective and safe. [6]
2. Medications (pills) – For widespread dystonia (e.g., trihexyphenidyl, baclofen, levodopa for specific types).
3. Deep Brain Stimulation (DBS) – A surgical option for severe, medication-resistant dystonia. A pacemaker-like device is implanted in the brain to control abnormal signals. [10]
4. Physiotherapy and Occupational Therapy – To maintain movement and function.

Is it Curable?

Most types of dystonia are chronic (lifelong) but very treatable. Botox injections can dramatically improve symptoms in focal dystonia. Some rare types (e.g., Dopa-Responsive Dystonia, Wilson's Disease) can be treated with medication and may improve significantly.

Key Counselling Points

1. Chronic but Treatable: "Dystonia is usually lifelong, but symptoms can be controlled very well with regular Botox injections or medications."
2. Botox Works Well: "Injections every 3 months are very effective for neck, eyelid, and voice dystonia. Most people see significant improvement."
3. Not Life-Threatening: "Dystonia is not life-threatening or degenerative (it does not damage your brain). It affects quality of life, but treatments are available."
4. Support Available: "Organizations like the Dystonia Medical Research Foundation and Dystonia Society UK provide support, information, and resources."

Where Can I Get More Information?

• Dystonia Society UK: dystonia.org.uk
• Dystonia Medical Research Foundation (USA): dystonia-foundation.org

---

17. Quality Markers and Audit Standards

---

18. Historical Context

• Term "Dystonia" Coined: Hermann Oppenheim (1911) described "Dystonia Musculorum Deformans" in children with progressive generalised dystonia.
• Botulinum Toxin for Dystonia: First used by Alan Scott (1980s) for strabismus, then rapidly adopted for blepharospasm and cervical dystonia. Revolutionised focal dystonia management. FDA approved for cervical dystonia (2000).
• DYT1 Gene Discovery: Ozelius et al. (1997) identified TOR1A (DYT1) mutation causing early-onset generalised dystonia, particularly in Ashkenazi Jewish population.
• Deep Brain Stimulation: First DBS for dystonia in 1990s. Vidailhet et al. (2005) landmark RCT confirmed efficacy of bilateral GPi DBS for primary generalised dystonia. [10] NICE approved DBS for dystonia (2006).

---

19. References

1. Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord. 2013;28(7):863-873. PMID: 23649720

2. Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv Neurol. 1998;78:1-10. PMID: 9750897

3. Steeves TD, Day L, Dykeman J, et al. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord. 2012;27(14):1789-1796. PMID: 23114997

4. Defazio G, Jankovic J, Giel JL, Papapetropoulos S. Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov. 2013;3:tre-03-193-4374-2. PMID: 24255801

5. Sheehy MP, Marsden CD. Writers' cramp—a focal dystonia. Brain. 1982;105(Pt 3):461-480. PMID: 7104663

6. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2016;86(19):1818-1826. PMID: 27164716

7. van Harten PN, Hoek HW, Kahn RS. Acute dystonia induced by drug treatment. BMJ. 1999;319(7210):623-626. PMID: 10473488

8. European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol. 2012;56(3):671-685. PMID: 22340672

9. Pekmezovic T, Ilic NV, Svetel M, et al. Quality of life in patients with focal dystonia. Clin Neurol Neurosurg. 2009;111(2):161-164. PMID: 18995953

10. Vidailhet M, Vercueil L, Houeto JL, et al. Bilateral deep-brain stimulation of the globus pallidus in primary generalized dystonia. N Engl J Med. 2005;352(5):459-467. PMID: 15689584

11. Bressman SB, Raymond D, Fuchs T, et al. Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study. Lancet Neurol. 2009;8(5):441-446. PMID: 19345147

12. Neychev VK, Gross RE, Lehéricy S, et al. The functional neuroanatomy of dystonia. Neurobiol Dis. 2011;42(2):185-201. PMID: 21303695

13. Quartarone A, Hallett M. Emerging concepts in the physiological basis of dystonia. Mov Disord. 2013;28(7):958-967. PMID: 23893452

14. Byl NN, Merzenich MM, Jenkins WM. A primate genesis model of focal dystonia and repetitive strain injury: I. Learning-induced dedifferentiation of the representation of the hand in the primary somatosensory cortex in adult monkeys. Neurology. 1996;47(2):508-520. PMID: 8757029

15. Segawa M, Hosaka A, Miyagawa F, et al. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol. 1976;14:215-233. PMID: 945938

16. Jankovic J. Medical treatment of dystonia. Mov Disord. 2013;28(7):1001-1012. PMID: 23893456

17. Trompetto C, Currà A, Buccolieri A, et al. Botulinum toxin changes intrafusal feedback in dystonia: a study with the tonic vibration reflex. Mov Disord. 2006;21(6):777-782. PMID: 16463349

18. Kupsch A, Benecke R, Müller J, et al. Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med. 2006;355(19):1978-1990. PMID: 17093249

19. Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet. 1997;17(1):40-48. PMID: 9288096

20. Balint B, Bhatia KP. Dystonia: an update on phenomenology, classification, pathogenesis and treatment. Curr Opin Neurol. 2014;27(4):468-476. PMID: 24978368

---

Last Reviewed: 2026-01-08 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Dystonia diagnosis and management should be performed by qualified neurologists and movement disorder specialists. This content does not replace professional medical advice. If you have symptoms of dystonia, consult a neurologist or movement disorders specialist.